Short Interest Runner: Xtant Medical Holdings Incorporated (NYSEMKT:XTNT) Shorted Shares Increased By 1.14%

November 22, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest Runner: Xtant Medical Holdings Incorporated (NYSEMKT:XTNT) Shorted Shares Increased By 1.14%

The stock of Xtant Medical Holdings Incorporated (NYSEMKT:XTNT) registered an increase of 1.14% in short interest. XTNT’s total short interest was 88,900 shares in November as published by FINRA. Its up 1.14% from 87,900 shares, reported previously. With 198,800 shares average volume, it will take short sellers 0 days to cover their XTNT’s short positions. The short interest to Xtant Medical Holdings Incorporated’s float is 1.39%. The stock increased 8.00% or $0.04 on November 21, hitting $0.54. Xtant Medical Holdings Inc (NYSEMKT:XTNT) has declined 78.49% since April 20, 2016 and is downtrending. It has underperformed by 83.04% the S&P500.

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, makes and markets regenerative medicine products and medical devices for domestic and international markets. The company has a market cap of $6.58 million. The Firm operates through the development, manufacture and marketing of regenerative medical products and devices segment. It currently has negative earnings. The Company’s biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts.

XTNT Company Profile

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., incorporated on August 8, 2006, develops, makes and markets regenerative medicine products and medical devices for domestic and international markets. The Firm operates through the development, manufacture and marketing of regenerative medical products and devices segment. The Company’s biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and a range of 3Demin products, as well as other allografts. The Company’s products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries.

More news for Xtant Medical Holdings Inc (NYSEMKT:XTNT) were recently published by: Seekingalpha.com, which released: “Xtant Medical Holdings’ (XTNT) CEO Dan Goldberger on Q3 2016 Results …” on November 08, 2016. Globenewswire.com‘s article titled: “Xtant Medical Announces FDA Approval of OsteoSelect(R) PLUS” and published on August 25, 2015 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>